Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343080 | 0.89 | RAB9A (0.38) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1342825 | 0.87 | RAB9A (0.45) | AVPR1BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5904379 | 0.84 | MAPT (0.36) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL5904340 | 0.83 | DYRK1A (0.37) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL6696138 | 0.83 | MAPT (0.36) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL5904383 | 0.83 | MEN1 (0.37) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1342591 | 0.81 | SMN1; SMN2 (0.39) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1339659 | 0.79 | MAPT (0.47) | AVPR1BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1343156 | 0.79 | RAB9A (0.44) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1341889 | 0.77 | MAPT (0.41) | MEN1KMT2ANPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | AVPR1B 4744/4885MEN1 4426/4885KMT2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.